Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cagrilintide/semaglutide - Novo Nordisk

Next Previous
X
Search
Drug Profile

Cagrilintide/semaglutide - Novo Nordisk

Alternative Names: CagriSema; NN-9388; Semaglutide/Cagrilintide - Novo Nordisk

Latest Information Update: 07 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Class Antihyperglycaemics; Glucagon-like peptides; Hepatoprotectants; Obesity therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action Amylin receptor agonists; Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Obesity; Type 2 diabetes mellitus
  • Phase II Alcoholic liver disorders

Most Recent Events

  • 07 Aug 2024 Novo Nordisk plans a phase III REIMAGINE 5 trial for Type 2 diabetes mellitus (Adjunctive treatment) in USA, Australia, Brazil, Canada, Germany, Greece, Hungary, India, Israel, Poland, Romania, Spain and Taiwan (SC) in November 2024 (NCT06534411)
  • 17 Jul 2024 Phase-III clinical trials in Type 2 diabetes mellitus in Poland, Serbia, China (SC) prior to July 2024 (NCT06323174)
  • 17 Jul 2024 Phase-III clinical trials in Obesity in Argentina, Brazil, Colombia, France, Germany, India, Malaysia, Mexico, Netherlands, Poland, Serbia, South Africa, and Turkey (SC) prior to July 2024 (NCT05669755)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top